Chapter 6. Diagnostic Aspects of Cardiovascular Toxicity of Antitumor Drugs

  1. Giorgio Minotti
  1. Michael S. Ewer1 and
  2. Thomas M. Suter2

Published Online: 9 APR 2010

DOI: 10.1002/9780470660379.ch6

Cardiotoxicity of Non-Cardiovascular Drugs

Cardiotoxicity of Non-Cardiovascular Drugs

How to Cite

Ewer, M. S. and Suter, T. M. (2010) Diagnostic Aspects of Cardiovascular Toxicity of Antitumor Drugs, in Cardiotoxicity of Non-Cardiovascular Drugs (ed G. Minotti), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470660379.ch6

Editor Information

  1. University Campus Bio-Medico, CIR and Drug Sciences, and Alberto Sordi Foundation-Research Institute on Aging, Via Alvaro del Portillo 21, 00128 Rome, Italy

Author Information

  1. 1

    The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA

  2. 2

    Swiss Cardiovascular Center, University Hospital Bern, Inselspital, CH-3010 Bern, Switzerland

Publication History

  1. Published Online: 9 APR 2010
  2. Published Print: 16 APR 2010

ISBN Information

Print ISBN: 9780470772744

Online ISBN: 9780470660379

SEARCH

Keywords:

  • cardiovascular toxicity and antitumor drugs - diagnostic aspects;
  • type1 and 2 treatment-related cardiotoxic agents;
  • anthracyclins and cardiotoxicity - mechanisms;
  • type 1 agents-associated cardiac abnormalities - necrosis;
  • type 1 agents and cardiotoxicity clinical spectrum;
  • type 1 agents augmented toxicity - age and hypertension;
  • trastuzumab-associated cardiotoxicity;
  • myocardial dysfunction - diagnostic aspects;
  • cardiac ultrasound - echocardiography;
  • MUGA - multi-gated scans

Summary

This chapter contains sections titled:

  • Introduction

  • Agents that Result in Contractile Dysfunction

  • Diagnostic Aspects of Myocardial Dysfunction

  • Cardiac Ultrasound

  • References